-
公开(公告)号:US08022222B2
公开(公告)日:2011-09-20
申请号:US12161366
申请日:2007-01-24
申请人: Thomas D. Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
发明人: Thomas D. Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
IPC分类号: C07D417/00 , A61K31/44
CPC分类号: C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
摘要: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
摘要翻译: 提供式I化合物,其中R 2,L,Z,Y,G和R 1如本文所定义,其可用于治疗和/或预防由缺乏葡萄糖激酶水平的活性介导的疾病或病症,或可由 激活葡萄糖激酶,包括但不限于糖尿病,葡萄糖耐量降低,IFG(空腹血糖受损)和IFG(空腹血糖受损)),以及其他疾病和病症如本文讨论的疾病和病症。
-
公开(公告)号:US20100099713A1
公开(公告)日:2010-04-22
申请号:US12524327
申请日:2008-01-16
申请人: Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
发明人: Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
IPC分类号: A61K31/4439 , C07D417/12 , A61P3/10 , C07D417/14
CPC分类号: C07D495/04 , C07D417/14
摘要: Provided are compounds having the Formula I or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
摘要翻译: 提供具有式I的化合物或其盐,其中R2,L,R3,R11,D2和R13如本文所定义,其可用于治疗和/或预防由缺乏葡萄糖激酶水平的活性介导的疾病,例如 糖尿病 还提供了治疗或预防以葡萄糖激酶不足活性为特征的疾病和病症的方法,或者可以通过激活葡糖激酶治疗。
-
公开(公告)号:US09187462B2
公开(公告)日:2015-11-17
申请号:US14237143
申请日:2012-08-03
申请人: James F. Blake , Huifen Chen , Mark Joseph Chicarelli , Jason Demeese , Rustam Ferdinand Garrey , John Gaudino , Lewis Gazzard , Robert J. Kaus , Samuel Kintz , Peter J. Mohr , David A. Moreno , Jacob Schwarz , Christopher S. Siedem , Eli M. Wallace
发明人: James F. Blake , Huifen Chen , Mark Joseph Chicarelli , Jason Demeese , Rustam Ferdinand Garrey , John Gaudino , Lewis Gazzard , Robert J. Kaus , Samuel Kintz , Peter J. Mohr , David A. Moreno , Jacob Schwarz , Christopher S. Siedem , Eli M. Wallace
IPC分类号: A61K31/517 , C07D239/84 , C07D405/14 , C07D403/12
CPC分类号: C07D405/14 , C07D403/12
摘要: Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
摘要翻译: 具有式(I)的化合物,其中本文定义的R1,R2,R3和Ar是ERK激酶的抑制剂。 还公开了用于治疗过度增殖性疾病的组合物和方法。
-
公开(公告)号:US20090247526A1
公开(公告)日:2009-10-01
申请号:US12161366
申请日:2007-01-24
申请人: Thomas D. Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
发明人: Thomas D. Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
IPC分类号: A61K31/5377 , C07D417/12 , C07D413/14 , C07D409/14 , A61P3/10 , A61K31/497 , C07D417/02 , A61K31/4439
CPC分类号: C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
摘要: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
摘要翻译: 提供式I化合物,其中R 2,L,Z,Y,G和R 1如本文所定义,其可用于治疗和/或预防由缺乏葡萄糖激酶水平的活性介导的疾病或病症,或可由 激活葡萄糖激酶,包括但不限于糖尿病,葡萄糖耐量降低,IFG(空腹血糖受损)和IFG(空腹血糖受损)),以及其他疾病和病症如本文讨论的疾病和病症。
-
公开(公告)号:US20150087664A1
公开(公告)日:2015-03-26
申请号:US14237143
申请日:2012-08-03
申请人: James F. Blake , Huifen Chen , Mark Joseph Chicarelli , Jason Demeese , Rustam Ferdinand Garrey , John Gaudino , Lewis Gazzard , Robert J. Kaus , Samuel Kintz , Peter J. Mohr , David A. Moreno , Jacob Schwartz , Christopher S. Siedem , Eli M. Wallace
发明人: James F. Blake , Huifen Chen , Mark Joseph Chicarelli , Jason Demeese , Rustam Ferdinand Garrey , John Gaudino , Lewis Gazzard , Robert J. Kaus , Samuel Kintz , Peter J. Mohr , David A. Moreno , Jacob Schwartz , Christopher S. Siedem , Eli M. Wallace
IPC分类号: C07D405/14 , C07D403/12
CPC分类号: C07D405/14 , C07D403/12
摘要: Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
摘要翻译: 具有式(I)的化合物,其中本文定义的R1,R2,R3和Ar是ERK激酶的抑制剂。 还公开了用于治疗过度增殖性疾病的组合物和方法。
-
公开(公告)号:US08431713B2
公开(公告)日:2013-04-30
申请号:US12524327
申请日:2008-01-16
申请人: Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
发明人: Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Rustam Ferdinand Garrey , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner
IPC分类号: A61K31/44 , C07D213/55
CPC分类号: C07D495/04 , C07D417/14
摘要: Provided are compounds having the Formula I or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
摘要翻译: 提供具有式I的化合物或其盐,其中R2,L,R3,R11,D2和R13如本文所定义,其可用于治疗和/或预防由缺乏葡萄糖激酶水平的活性介导的疾病,例如 糖尿病 还提供了治疗或预防以葡萄糖激酶不足活性为特征的疾病和病症的方法,或者可以通过激活葡糖激酶治疗。
-
-
-
-
-